Dycerin-GM

Quick links

Choose a section

Quick links to important sections

Advertisements

Dycerin-GM

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Dycerin-GM

Property Description
Active Ingredients Diacerein, Glucosamine (often with Methylsulfonylmethane (MSM))
Form Tablet or Hard Capsule (Oral preparation)
Pharmacological Class Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA)
General Purpose Long-term management of degenerative joint symptoms
Origin Semi-synthetic derivative (Diacerein) and Amino sugar (Glucosamine)

What Type of Medicine is Dycerin-GM?

Dycerin-GM is a combination medicine administered via the oral route as a solid preparation. It is classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA) and is considered a chondroprotective agent. This therapeutic classification is clinically recognized for medicines aimed at providing sustained relief in chronic joint conditions. The brand itself, Dycerin-GM, represents a fixed-dose combination, which simplifies the regimen for patients compared to taking multiple separate components.

Active Ingredients and Composition

This medicine is composed of the active ingredients Diacerein and Glucosamine, frequently accompanied by Methylsulfonylmethane (MSM). Diacerein is an anthraquinone derivative, and Glucosamine is an amino sugar. Glucosamine is often incorporated as the sulfate salt, a key precursor molecule essential for the body to form and maintain joint cartilage. Pharmacological studies indicate that Diacerein's active metabolite works by inhibiting the effects of the inflammatory substance Interleukin-1. This combination is distinctive as it addresses both structural support and the underlying inflammatory pathways associated with joint degeneration.

General Purpose for Joint Health

The general therapeutic purpose of Dycerin-GM is the long-term management of pain and stiffness associated with degenerative joint diseases, such as osteoarthritis. A typical neutral use scenario involves adults seeking continuous support for joint discomfort, especially when the condition affects large joints like the knees. The formulation's primary goal is to provide lasting symptomatic relief and support overall joint function, rather than offering immediate, short-term pain suppression. The combined use of Glucosamine and Diacerein serves as a fundamental background treatment for the condition.

Regulatory References

  1. European Medicines Agency (EMA)
  2. Diacerein plus glucosamine study [NIH PubMed]
Advertisements

What side effects are possible with Dycerin-GM?

Possible side effects and safety information

The officially documented safety profile of Dycerin-GM (Diacerein and Glucosamine) is characterized by a high frequency of gastrointestinal effects and specific, serious risks primarily associated with the Diacerein component.

Adverse Reactions by Frequency (Diacerein)

Frequency Classification Examples of Reactions
Very Common (May affect > 1 in 10 people) Diarrhoea, Abdominal pain
Common (May affect up to 1 in 10 people) Frequent bowel movements, Flatulence, Pruritus (itching), Rash
Uncommon Elevated hepatic enzyme levels in serum

These effects are typically categorized under Gastrointestinal Disorders and Skin and Subcutaneous Tissue Disorders. Diarrhoea often begins soon after treatment initiation but generally abates with continuing treatment, as documented in regulatory sources.

Serious Safety Considerations

Official labeling emphasizes the risk of serious adverse reactions, particularly regarding the liver. Cases of Acute Liver Injury and Hepatitis, including symptomatic injury, have been reported, with most cases occurring during the first months of treatment. Severe diarrhoea can also lead to complications like dehydration and electrolyte imbalance. Rare but serious reactions like Stevens-Johnson syndrome (SJS) have also been documented.

Population-Specific Safety Constraints

Use of the Diacerein component is contraindicated in any patient with established liver disease or a history of liver disease. Furthermore, the medicine is not recommended for use in older adults (aged 65 years or above) due to the increased risk of severe diarrhoea and associated complications, as mandated by regulatory authorities. Caution is also noted for patients with shellfish allergy, related to the Glucosamine component.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented overdose profile for Dycerin-GM (containing Diacerein) as described in regulatory documents. This content is non-advisory and reflects label instructions for over-exposure management.


Documented Overdose Manifestations

Regulatory sources indicate that an accidental or intentional overdose of Dycerin-GM may present with specific symptoms. The most notable manifestation linked to the Diacerein component is profuse diarrhea. Other reported symptoms include headache, dizziness, disorientation, and general gastrointestinal upset (nausea, vomiting, and constipation).

Life-Threatening Risks and Supportive Management

Overdose-induced profuse diarrhea carries a risk of serious complications, namely severe dehydration and subsequent electrolyte disorders. These conditions can be life-threatening if not addressed promptly.

No specific antidote is listed for Dycerin-GM overdose. Management focuses entirely on supportive and symptomatic treatment, with the primary intervention being the correction of fluid and electrolyte imbalances caused by excessive fluid loss.

Emergency Response Instruction

Official regulatory labeling dictates that in the event of an overdose or accidental ingestion of excessive quantities, immediate medical attention is required. Patients or caregivers must consult a doctor immediately or visit the nearest hospital or Poison Control Center right away. Specific caution is noted for elderly patients and those with severe renal impairment.

Advertisements

Therapeutic Uses of Dycerin-GM

What Dycerin-GM Treats: Main Uses and Benefits

The therapeutic domain of Dycerin-GM is applied in conditions requiring sustained symptomatic support, particularly for osteoarthritis (OA), the most common form of degenerative joint disease. Its use is specifically focused on relieving symptoms of OA, particularly when the condition affects the hip or knee. This medicine belongs to the class of Symptomatic Slow-Acting Drugs in Osteoarthritis (SYSADOA) and is relevant for sustained symptomatic support.

It is commonly used to help manage symptom clusters that include chronic joint pain, tenderness, and stiffness that restricts mobility. The medication is applied when symptoms create noticeable functional strain and interfere with daily functioning, often targeting the mild to moderate stages of the disease in adult and older adult patient groups. It assists with maintaining functional stability and supports general well-being during symptomatic phases of the condition.


Quick Fact: Relief for Joint Stiffness and Pain

The medicine is commonly used to help with symptomatic discomfort related to symptoms related to chronic physical discomfort, applied across domains where additional symptomatic support is needed, and contributing to improved day-to-day comfort.

Regulatory References

  1. European Medicines Agency referral for Diacerein
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Regulatory agencies define strict population limits for Dycerin-GM (Diacerein + Glucosamine) based on specific health conditions and age groups.

Classification Population or Condition
Contraindicated Current or history of liver disease; Pregnancy and breastfeeding; Hypersensitivity to any component; Inflammatory bowel disease (e.g., Crohn's, ulcerative colitis)
Not Recommended Patients aged 65 years and above; Children and adolescents (generally under 15 or 18 years)

Dycerin-GM is primarily indicated for use in adult patients. Due to the risk of severe diarrhea, the medicine is not recommended for the elderly population (ge 65 years). Use is formally contraindicated during both pregnancy and lactation, and for any individual with a history of liver disease. Furthermore, specific limitations apply to those with severe renal insufficiency, and caution is advised for patients with diabetes or shellfish allergies.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile

The medicine's active components, Diacerein and Glucosamine, have documented interactions that fall into pharmacodynamic (PD) and pharmacokinetic (PK) classifications as established by regulatory authorities. Every interaction described is based strictly on governmental label information.

Interaction Category Interacting Substance / Condition Regulatory Constraint
Contraindicated Combinations Laxatives Co-administration is restricted due to the synergistic PD risk of severe diarrhoea.
Population Restriction Current or History of Liver Disease Use is formally restricted due to the documented heightened risk of hepatic injury from Diacerein.

Pharmacodynamic Interactions Co-administration with Diuretics (Thiazides, Loop) and Cardiac Glycosides (such as Digitoxin or Digoxin) requires caution. These combinations are documented to increase the risk of arrhythmia because the Diacerein component carries a risk of hypokalemia. Furthermore, the Glucosamine component is documented to enhance the effect of Warfarin and other Coumarin anticoagulants, a finding that necessitates attention to the anticoagulant outcome.

Pharmacokinetic and Timing Rules The official labeling includes a timing-based separation rule for certain medicines. Antacids containing aluminum, calcium, or magnesium salts must be taken separately from Diacerein by an interval of greater than two hours. This rule is in place to prevent the documented reduction in Diacerein's absorption. Lastly, due to the officially noted risk of hepatic adverse events, regulatory documents advise limiting Alcohol intake during Diacerein use.

Advertisements

Mechanism of Action

️ How Dycerin-GM Works

Dycerin-GM operates through a dual mechanistic approach, targeting both the catabolism and anabolism of joint cartilage via the complementary actions of its two components. The mechanism is constrained by the time required for molecular signaling and cellular turnover to manifest.

ⓒ Modulation of Catabolic Inflammation

The component Diacerein acts via its active metabolite, Rhein, which specifically inhibits the pro-inflammatory cytokine, Interleukin-1 beta (IL-1beta). This molecular interaction suppresses the catabolic cascade that triggers destructive enzymes, such as Matrix Metalloproteinases (MMPs). This molecular cascade results in the suppression of catabolism and the maintenance of tissue integrity.

ⓘ Support for Cartilage Matrix Anabolism

The component Glucosamine supplies an essential aminosaccharide precursor that is incorporated by chondrocytes into the Hexosamine Biosynthesis Pathway (HBP). This provides the aminosaccharide substrate for the synthesis of structural macromolecules, Glycosaminoglycans (GAGs) and Proteoglycans. This mechanism contributes to anabolism and influences the production of macromolecules that regulate the viscoelastic properties of the joint environment.

ⓟ Systemic Consequence of Slow Mechanism

The combined effect involves the simultaneous modulation of catabolic signals and the enhancement of anabolic pathways. The mechanism's reliance on modifying the kinetics of cellular synthesis and molecular signaling dictates an inherently slow-onset physiological response, which requires weeks to months to reach its full effect.

Advertisements

Dosage and Administration Information

How to Use Dycerin-GM: Administration Guidelines

The following details the use of Dycerin-GM (a combination of Diacerein, Glucosamine, and Methylsulfonylmethane).

Administration Scope

Scope Element Instruction
Route of administration Oral (by mouth)
Dosage Form Tablet
Dosing schedule Typically one tablet per dose, taken once or twice daily.
Timing in relation to meals Must be taken with food or immediately after a meal.
Special procedural conditions The tablet must be swallowed whole with water. Do not crush, chew, or break.

Procedural and Population Rules

Procedural Structure:

  1. Take the prescribed dose (one tablet).
  2. Ensure the tablet is taken during or immediately following a meal.
  3. Swallow the tablet whole with a glass of water; alteration of the tablet is prohibited.
  4. Maintain the prescribed once or twice daily frequency.

Age-Group Administration Rules:

  • Pediatric Use: Dycerin-GM is not recommended for use in children and adolescents under 18 years of age.

Missed-Dose Rules:

  • If a dose is missed, take it as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed one. Do not take a double dose to compensate.

These instructions define the standardized method for administering the medicine, focusing on the physical method, timing, and population restrictions.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dycerin-GM


Evidence for Use in Knee and Hip Osteoarthritis

Dycerin-GM (or its key active components) was evaluated in studies examining individuals with knee and hip osteoarthritis, which are conditions marked by functional limitations. Studies have primarily focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in research conducted over defined time intervals.

Studies conducted for this indication were often randomized controlled trials, which are considered a high-quality type of evidence. These trials generally examine data show patterns related to Dycerin-GM versus a placebo or sometimes other interventions. Findings across various research indicate patterns observed in the studies related to outcomes related to physical discomfort and changes in daily functioning or activity level, particularly when research explored short-term symptom changes.

However, the evidence quality varies across studies, and findings were mixed in some instances. Some trials showed data show patterns related to smaller measured changes when compared to placebo, while other studies reported data show patterns related to differing measured changes. The research highlights changes measured during the study period, with evidence describing how symptoms evolved in the observed populations during the defined time intervals. The collective evidence contributes to the broader evidence landscape.


Long-term Studies and Follow-up

Research has also explored how Dycerin-GM (or its main components) was evaluated in studies for conditions characterized by fluctuating or episodic manifestations over longer timeframes. These studies monitored patients to understand the durability of the response beyond the typical few weeks or months of an initial trial, focusing on observed responses over defined time intervals.

Currently, long-term effects are not fully established, as follow-up durations were limited in many of the key studies. Evidence for outcomes sustained over several years remains insufficient. Research suggests patterns observed in the studies related to outcomes related to physical discomfort over defined time intervals in a subset of participants, but there is limited information for long-term outcomes, such as data related to long-term outcomes monitoring physiological strain or stress remains limited. Because the data are still emerging, certainty remains low regarding the effects of using the supplement for a long duration.


Evidence in Special Populations

Studies exploring the effects of Dycerin-GM have primarily been conducted in middle-aged adults with mild to moderate osteoarthritis. This area will outline studies that have specifically evaluated different groups.

  • Older Adults: Research exploring short-term symptom changes was evaluated in older adults (often defined as those over 70) and was observed in studies examining daily-life functioning. While findings indicate patterns related to similar measured changes as observed in other studied populations, data for certain groups remain insufficient, especially those with significant co-occurring medical conditions.
  • Other Conditions: Dycerin-GM was studied for use in people who also have other conditions. However, evidence derived from settings with varying symptom burdens remains limited for people with complicated or severe pre-existing conditions.

Data for certain groups remain insufficient. Specifically, there is very limited, or no, robust evidence available on the use of Dycerin-GM in children (under 18) or in pregnant or breastfeeding populations. The results apply only to the populations studied, and data for certain groups remain insufficient.


What is Still Uncertain About Dycerin-GM

Despite the body of research, several important questions about Dycerin-GM remain unanswered, highlighting areas where more research is needed. This section synthesizes the main evidence gaps observed in the research.

One area of uncertainty is that research has not fully clarified the evaluation of Dycerin-GM in studies exploring short-term symptom changes. Also, comparative evidence is lacking, meaning there are few head-to-head trials that directly compared Dycerin-GM with other interventions where research examined outcomes related to physical discomfort.

Overall, while the research helps show what has been observed so far, many of the sample sizes were modest, and follow-up durations were limited. This means that while studies contribute to understanding symptom patterns, the full picture of the evidence base for conditions marked by functional limitations is still emerging. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. NICE Guideline NG212: Osteoarthritis in over 16s: diagnosis and management.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dycerin-GM (FAQ)


Q: How long does it usually take for Dycerin-GM to start working?

A: This medicine is classified as a slow-acting drug for joint conditions. Its mechanism involves a gradual modification of cartilage synthesis and anti-inflammatory signals. Regulatory sources indicate that because this is an inherently slow biological process, it typically requires several weeks to months of consistent use to achieve its full intended effect.

Q: If I miss a dose of Dycerin-GM, what is the usual guidance?

A: Official patient information provides standardized guidance for missed doses. If a dose is remembered soon after the scheduled time, it may be taken. However, if it is almost time for the next dose, the instruction is to skip the missed one. It is officially advised never to take a double dose to compensate for a forgotten one.

Q: Can Dycerin-GM be taken with other supplements, like Vitamin D?

A: Official drug labels list known interactions with specific pharmaceutical drug classes, such as anticoagulants or diuretics. General dietary supplements, such as Vitamin D, are not usually addressed within the official medical labeling’s list of known interactions.

Q: If I have a history of ulcers, can I still use Dycerin-GM?

A: Official labeling contraindicates use for people with Inflammatory Bowel Disease (IBD) due to the documented risk of severe diarrhea. While ulcers are a different condition, the medicine's potential for gastrointestinal upset suggests caution is warranted. Patients with a history of GI issues should refer to their prescriber for guidance.

Q: Do I need to take Dycerin-GM with food, or can I take it on an empty stomach?

A: Official drug administration guidelines state that Dycerin-GM must be taken with food or immediately following a meal. This is a mandatory condition specified in regulatory documents to ensure proper use.

Q: Is Dycerin-GM a type of painkiller or is it something different?

A: Dycerin-GM is officially classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA). This means its primary role is the long-term management of chronic joint symptoms, distinguishing it from conventional, fast-acting pain relievers (analgesics or NSAIDs).

Q: Is Dycerin-GM the same as other arthritis medications I've seen?

A: This medicine is classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA). This therapeutic classification distinguishes it from other common arthritis medications, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or corticosteroids.

Q: Why do some people say Dycerin-GM is for bones and others say joints?

A: The medicine's official mechanism focuses on supporting joint cartilage and inhibiting the destructive enzymes. It is used to manage osteoarthritis, which is defined as a disease affecting the entire joint structure, including the cartilage, the bone underneath, and the surrounding tissue.

Q: Is it normal to feel a mild stomach upset when starting Dycerin-GM?

A: Official safety documents list diarrhoea and abdominal pain as very common side effects. These gastrointestinal issues are noted to often occur upon treatment initiation but generally lessen with continued use, according to regulatory sources.

Q: Are there any common foods or drinks that interact badly with Dycerin-GM?

A: Official labeling advises limiting alcohol intake during use due to the documented risk of liver adverse events associated with the Diacerein component. No other specific foods are officially listed as having interactions; the medicine is only recommended to be taken with food.

Q: Is it safe to take paracetamol (acetaminophen) while using Dycerin-GM?

A: The official labels list known drug interactions with specific classes of medicines (such as blood thinners or antacids). Paracetamol (acetaminophen) is not one of the specific medicines named in the official drug interaction warnings.

Q: Can people with high blood pressure use Dycerin-GM?

A: Official drug labels do not list high blood pressure (hypertension) as a specific contraindication. However, the medicine has known interactions with certain heart medicines, such as diuretics and cardiac glycosides, which is a situation requiring attention and discussion with a healthcare provider.

Q: What does the 'GM' part of the name Dycerin-GM refer to?

A: The 'GM' portion is not an official designation but is commonly used to reference the active components Glucosamine (G) and Methylsulfonylmethane (M). These components are combined with Diacerein in this specific fixed-dose formulation.

Q: Is Dycerin-GM an over-the-counter medicine in some countries?

A: In many countries, including those regulated by major agencies like the EMA, the Diacerein component means Dycerin-GM is typically classified as a prescription-only medicine.

Q: Is Dycerin-GM approved by the FDA or other major health agencies?

A: The individual components of this medicine are reviewed and regulated by various health authorities globally, including the EMA. The specific fixed-dose combination, Dycerin-GM, is approved and regulated according to the specific national health authorities where it is made available.

Q: Are there long-term studies available about using Dycerin-GM for many years?

A: Regulatory reviews acknowledge that the long-term effects are not fully established beyond the typical few months of initial studies. Evidence for outcomes sustained over several years is considered insufficient in the core documentation, indicating an area where further research is needed.

Q: What is the difference between Dycerin-GM and generic alternatives?

A: A generic medicine is required to contain the exact same active ingredients in the same strength as the brand-name product. The key differences usually exist in the inactive ingredients (excipients), the physical appearance of the pill, and often the cost.

Q: Does Dycerin-GM cause drowsiness or affect driving?

A: The official label for one of the components (Diacerein) notes that dizziness has been reported as a possible undesirable effect. Dizziness may affect the ability to drive or operate machinery, and official product information suggests caution.

Q: What is the earliest age someone is generally eligible to use Dycerin-GM?

A: Dycerin-GM is primarily indicated for use in adult patients. Official regulatory documents state that the medicine is not recommended for use in children and adolescents, generally defined as individuals 18 years of age and below.

Q: Why does Dycerin-GM sometimes take weeks or months to show an effect?

A: The medicine's mechanism works by modifying cellular signaling and synthesis (like cartilage building) and anti-inflammatory pathways. Regulatory documents explain that this type of deep biological change is an inherently slow process that requires time to accumulate and manifest clinically.

Q: What should I do if I think I'm having a rare side effect from Dycerin-GM?

A: Official health agencies mandate that patients report suspected serious or rare adverse effects. If a serious or unexpected reaction is suspected, patients are generally advised to contact a healthcare professional or use the official national adverse event reporting system.

Q: What should I watch out for when taking Dycerin-GM with cold or flu medicines?

A: Official drug labels list specific interactions only for certain prescription drug classes. Because over-the-counter cold and flu medicines contain various ingredients, patients are advised to review the components of these medicines for possible ingredients that may interact.

Q: Can men and women both use Dycerin-GM equally?

A: Official eligibility and usage restrictions focus on age and pre-existing health conditions, not gender. Clinical trials for the medicine's active components have included both male and female patients.

Q: Does Dycerin-GM affect blood sugar levels significantly?

A: Official warnings advise caution for patients with impaired glucose tolerance or diabetes. The Glucosamine component may affect blood sugar levels, and therefore close monitoring of blood sugar is advised for these patients.

Q: What are the signs that Dycerin-GM might not be working for a patient?

A: The medicine is for the long-term management of joint pain and stiffness. Official studies measure outcomes related to physical discomfort and daily functioning. A lack of expected improvement in these areas after the initial treatment period of several weeks to months would suggest the medicine is not providing the intended symptomatic relief.

Q: Does Dycerin-GM interfere with laboratory tests or blood work?

A: Yes, the Diacerein component is noted in regulatory documents to cause elevated hepatic enzyme levels in serum, which is a finding detected in blood work. It can also cause a dark discoloration of urine, which may interfere with some diagnostic tests.

Q: Are there any known issues with Dycerin-GM and alcohol consumption?

A: Official regulatory documents advise limiting alcohol intake. This warning is based on the officially noted risk of hepatic (liver) adverse events associated with the Diacerein component.

Advertisements

How should Dycerin-GM be stored and disposed of?

How to Store and Dispose of Dycerin-GM

Official regulatory guidelines establish specific requirements to ensure the proper storage and disposal of this medicine.

Storage Requirements

Condition Requirement
Temperature Store below 25 C or 30 C (refer to product label).
Protection Keep in a cool, dry place. Protect from direct sunlight, heat, and moisture.
Container Keep the medicine in its original, tightly closed container.
Child Safety Store out of sight and reach of children and pets.
Stability Do not use the medicine if it has passed the expiry date printed on the packaging.

️ Disposal Rules

Unused or expired Dycerin-GM must be disposed of safely to prevent accidental consumption. Typically, this involves mixing the medicine with an undesirable substance (such as dirt or used coffee grounds) and placing the mixture in a sealed container or bag before discarding it with household trash. Do not flush this medicine down the toilet or drain unless specifically instructed to do so by a healthcare professional or government program. Ensure that children and pets cannot consume the disposed-of product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dycerin-GM found in:

A-Z Index: